

1 **The iHealth-T2D study: Statistical analysis plan for a cluster randomised controlled trial with intensive family-**  
2 **based lifestyle modification programme to reduce type 2 diabetes risk amongst South Asians.**

3 Mirthe Muilwijk<sup>1\*</sup>, Marie Loh<sup>2,3\*</sup>, Sara Mahmood<sup>4</sup>, Saranya Palaniswamy<sup>3,5</sup>, Samreen Siddiqui<sup>6</sup>, Wnurinham  
4 Silva<sup>3</sup>, Gary S. Frost<sup>7</sup>, Heather M. Gage<sup>8</sup>, Marjo-Riitta Jarvelin<sup>3,5,9,10</sup>, Ravindra P. Rannan-Eliya<sup>11</sup>, Sajjad Ahmed<sup>12</sup>,  
5 Sujeet Jha<sup>6</sup>, Anuradhani Kasturiratne<sup>13</sup>, Prasad Katulanda<sup>14</sup>, Khadija I. Khawaja<sup>4</sup>, Jaspal S. Kooner<sup>15,16</sup>, Ananda R.  
6 Wickremasinghe<sup>13</sup>, Irene G.M. van Valkengoed<sup>1\*\*</sup>, John C. Chambers<sup>2,3\*\*</sup>

7 \* MM and ML contributed equally and are joint first authors.

8 \*\* IGMV and JCC contributed equally and are joint senior authors.

9 1: Amsterdam UMC, University of Amsterdam, Department of Public Health, Amsterdam Public Health research  
10 institute, Meibergdreef 9, Amsterdam, The Netherlands.

11 2: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.

12 3: Imperial College London, Department of Epidemiology and Biostatistics, School of Public Health, Imperial  
13 College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK.

14 4: Services Institute of Medical Sciences, Department of Endocrinology & Metabolism, Services Institute of  
15 Medical Sciences, Services Hospital, Ghaus ul Azam, Jail Road 54700, Lahore, Pakistan.

16 5: University of Oulu, Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu,  
17 Finland.

18 6: Max Healthcare, Institute of Endocrinology, Diabetes and Metabolism, Max Super Speciality Hospital, 2,  
19 Press Enclave Road, Skaet, New Delhi-110017, India.

20 7: Imperial College London, Faculty of Medicine, Imperial College Hammersmith Campus, DuCane Road, London  
21 W12 ONN, UK.

22 8: University of Surrey, Surrey Health Economics Centre, Department of Clinical and Experimental Medicine,  
23 University of Surrey, Leggett Building, Daphne Jackson Road, Guildford GU2 7WG, Surrey, UK

24 9: University of Oulu, Unit of Primary Care, Oulu University Hospital, Oulu, Finland.

25 10: Brunel University, Department of Life Sciences, College of Health and Life Sciences, Brunel University  
26 London, Kingston Lane, Uxbridge, Middlesex UB8 3PH, UK.

27 11: Institute for Health Policy, Institute for Health Policy, 72 Park Street, Colombo, 00200, Sri Lanka.

28 12: Punjab Institute of Cardiology, Jail Road, Shadman, Lahore, Punjab, Pakistan.

29 13: University of Kelaniya, Faculty of Medicine, University of Kelaniya, PO Box 06, Thalagolla Road, Ragama  
30 11010, Sri Lanka.

31 14: University of Colombo, Department of Clinical Medicine, Faculty of Medicine, University of Colombo, 25  
32 Kynsey Rd, Colombo 00800, Sri Lanka.

33 15: London Northwest University Healthcare NHS Trust, London Northwest University Healthcare NHS Trust,  
34 Uxbridge Road, Southall, Middlesex UB1 3HW, UK.

35 16: Imperial College London, National Heart and Lung Institute, Imperial College London, Hammersmith  
36 Hospital Campus, DuCane Road, London W12 ONN, UK.

37 Corresponding author: Mirthe Muilwijk, Phone: +31 020 566 13 73, Email: [m.muilwijk@amsterdammc.nl](mailto:m.muilwijk@amsterdammc.nl),  
38 ORCID iD: <https://orcid.org/0000-0002-3686-5116>

39

40

41

42

43

44

45

46

47 **Abstract:**

48 Background: South Asians are at high risk of type 2 diabetes (T2D). Lifestyle modification is effective at  
49 preventing T2D amongst South Asians, but the approaches to screening and intervention are limited by high-  
50 costs, poor scalability and thus low impact on T2D burden. An intensive family-based lifestyle modification  
51 programme for prevention of T2D was developed. The aim of the iHealth-T2D trial is to compare the  
52 effectiveness of this programme with usual care.

53 Methods: The iHealth-T2D trial is designed as a cluster randomised controlled trial (RCT) conducted at 120  
54 locations across India, Pakistan, Sri Lanka and the UK. A total of 3,682 South Asian men and women with age  
55 between 40-70 years without T2D but at elevated risk for T2D [defined by central obesity (waist circumference  
56  $\geq 95$ cm in Sri Lanka, or  $\geq 100$ cm in India, Pakistan and UK) and/or prediabetes (HbA1c  $\geq 6.0\%$ )] were included in  
57 the trial. Here we describe in detail the statistical analysis plan (SAP), which was finalised before outcomes  
58 were available to the investigators. The primary outcome will be evaluated after three years of follow-up after  
59 enrolment to the study, and is defined as T2D incidence in the intervention arm compared to usual care.  
60 Secondary outcomes are evaluated both after one and three years of follow-up and include biochemical  
61 measurements, anthropometric measurements, behavioural components and treatment compliance.

62 Discussion: The iHealth-T2D trial will provide evidence whether an intensive family-based lifestyle modification  
63 programme in South Asians who are at high risk for T2D is effective in the prevention of T2D. The data from the  
64 trial will be analysed according to this pre-specified SAP.

65 Ethics and dissemination: The trial was approved by the international review board of each participating study  
66 site. Study findings will be disseminated through peer-reviewed publications and in conference presentations.

67 Trial registration: EudraCT 2016-001350-18. Registered 14 April 2016 [https://www.hra.nhs.uk/planning-and-](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ihealth-t2d/)  
68 [improving-research/application-summaries/research-summaries/ihealth-t2d/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ihealth-t2d/); ClinicalTrials.gov NCT02949739.  
69 Registered 31 October 2016, <https://clinicaltrials.gov/ct2/show/NCT02949739>, First posted 31/10/2016.

70 **Keywords:** Type 2 diabetes, South Asian, Lifestyle intervention

71

## 72 Introduction

73 Type 2 diabetes (T2D) is the fifth leading cause of death worldwide(1) and a major contributor to the  
74 development of various comorbidities including coronary heart disease, stroke, peripheral vascular disease and  
75 end-stage renal failure(2). South Asians, who represent one-quarter of the world's population, are at high risk  
76 of T2D and its complications, both in the country of origin and after migration(3, 4). Key modifiable risk factors  
77 that could be targeted to delay or prevent the onset of T2D include behavioural factors such as diet and  
78 physical activity(5). In past decades evidence from “the Finnish Diabetes Prevention Study” and “the Diabetes  
79 Prevention Program” showed that targeting these behavioural factors may be effective to delay or prevent the  
80 onset of T2D(6, 7). A recent meta-analysis on 1,816 participants from six randomized controlled trials (RCTs)  
81 (four from Europe and two from India) has reported lifestyle modifications may also be effective among South  
82 Asian populations(8).

83 Although the studies conducted to date provide some support for the utility of lifestyle interventions for  
84 prevention of T2D amongst South Asians, there are significant limitations. First, completed studies conducted  
85 in India and Sri Lanka are limited to local settings and small sample sizes, and there are no studies reported  
86 from Pakistan. Second, the evidence-based approach established by studies to prevent T2D among South  
87 Asians lack scalability and sustainability for T2D prevention, especially in low-middle income settings, since  
88 previous lifestyle interventions to prevent T2D were designed in a way that makes them labour-intensive and  
89 costly. To address these important limitations, we designed the iHealth-T2D trial in a way that makes the  
90 intervention scalable and sustainable in both low-middle income and high-income settings. The iHealth-T2D  
91 intervention aims to identify participants as being at risk for T2D based on parameters which include low-  
92 resource strategies such as waist circumference, and to improve cost-effectiveness and scalability of lifestyle  
93 modification through use of community health workers and a family-based lifestyle modification. Furthermore,  
94 we aimed to evaluate the effectiveness of the intervention in different cultural groups living in India, Pakistan,  
95 Sri Lanka and the UK, to improve generalisability. The objective of the iHealth-T2D trial is to investigate  
96 whether our family-based lifestyle modification delivered by community health workers is effective to prevent  
97 T2D amongst South Asians at high risk for T2D (based on central obesity or pre-diabetes), compared to usual  
98 care.

99 Here we report the details of the statistical analysis plan (SAP), prepared according to the published guidelines  
100 on the content of SAPs(9). This SAP includes details on the analyses of the primary objective, but does not  
101 include details on secondary questions nor the evaluation of cost-effectiveness. The cluster RCT is registered  
102 with EudraCT: 2016-001350-18 and ClinicalTrials.gov: NCT02949739. This SAP should be read in conjunction  
103 with the study protocol, which contains more details on the study rationale and design. The study protocol will  
104 be published and is until then available upon reasonable request.

### 105 **Summary study design**

106 The iHealth-T2D trial is designed as a cluster RCT amongst 3,682 South Asians at high risk for T2D at 120  
107 locations across India, Pakistan, Sri Lanka and the UK. The study design is summarised in *Figure 1.*, in brief: a  
108 total of 120 sites from a range of socio-economic settings were identified, comprising 30 sites in each of the  
109 four participating countries (India, Pakistan, Sri Lanka and the UK). The field-work sites were cluster  
110 randomised to either family-based lifestyle modification or usual care (1:1 allocation). At each field-work  
111 location we aimed to recruit 15 male and 15 female South Asians between the ages of 40 and 70 years old, at  
112 high risk, but free from T2D, were included. High risk for T2D was defined by central obesity (waist  
113 circumference  $\geq 95$ cm in Sri Lanka, or  $\geq 100$ cm in India, Pakistan and UK) and/or prediabetes (HbA1c $\geq 6.0\%$ ).  
114 Exclusion criteria included participants with known type 1 or type 2 diabetes, fasting glucose levels  $\geq 7.0$   
115 mmol/L, HbA1c levels  $\geq 6.5\%$ , BMI  $< 22$  kg/m<sup>2</sup>, pregnant or planning pregnancy, unstable residence or planning  
116 to relocate and serious illness.

117 The primary aim of the lifestyle modification sessions was the prevention of T2D, details on the various  
118 sessions can be found in the iHealth-T2D study protocol. In brief, participants in the lifestyle modification arm  
119 received family-based lifestyle modification delivered by a community health worker, consisting of 22 contact  
120 sessions over a period of 12 months. Participants in the usual care arm received a single diabetes prevention  
121 education session lasting 30-60 minutes delivered by a community health worker. Written material was  
122 distributed additionally. Both participants and community health workers could not be blinded to the  
123 treatment arm as the type of care given is clearly visible. They were, however, kept masked to outcome  
124 measurements and trial results. Participants were followed up annually, during a period of three years. Data  
125 were obtained by research nurses who were blinded to trial arms to reduce the risk of assessment bias.

126 Ethical approval was obtained from the Institutional Review Board in each participating country and at each  
127 research location before the start of the study. Information sheets and consent forms were made available in  
128 the major South Asian languages. Multilingual translators were available as required. Each participant provided  
129 informed consent. People unwilling or unable to provide consent were excluded from the study. The research  
130 complied with relevant national and international regulations and was carried out in line with the Declaration  
131 of Helsinki and the International Conference on Harmonization Guidelines.

### 132 **Study outcomes**

133 The effectiveness of the iHealth-T2D intervention will be evaluated at two time points, both after one and after  
134 three years of follow-up. After one year of follow-up secondary outcomes are evaluated, while after three  
135 years of follow-up both the primary outcome and secondary outcomes will be evaluated.

136 The primary outcome is defined as: T2D incidence in the intervention arm compared to the usual care arm after  
137 three years of follow-up in both groups of South Asians with central obesity and prediabetes. T2D incidence is  
138 defined as a physician diagnosis and being on treatment for T2D, or HbA1c levels  $\geq 6.5\%$  (10). The primary  
139 outcome will not be evaluated after one year of follow-up as power calculations were based on a three year  
140 follow-up duration.

141 Secondary outcomes include glucose, insulin, HOMA, total cholesterol, HDL cholesterol, triglycerides, blood  
142 pressure, waist circumference, weight, smoking status, alcohol use, physical activity, dietary intake, treatment  
143 compliance and dose delivered / received, are, therefore, evaluated both after one and three years of follow-  
144 up. The evaluation of secondary outcomes after one as well as three years of follow-up will allow for  
145 comparisons of both short- and long-term effects of the lifestyle intervention. In addition, subgroup analyses  
146 amongst participants included in the study based on HbA1c and/or waist circumference will be performed.

147 Study outcomes that will be reported but are not included in the current SAP are secondary questions which  
148 include changes in adiposity and glucose homeostasis amongst the extended family, psychosocial measures,  
149 cost effectiveness and implications of scaling up locally and nationally.

150 Power calculations performed before the start of the data collection in the first version of the trial protocol  
151 showed that the iHealth-T2D trial is well powered to assess the primary outcome (*Additional file 1*). These a

152 priori power calculation considered adjustment for multiple testing (a  $p < 0.017$ ), because the effects in the main  
153 analysis were calculated by subgroups based on a high risk for T2D either based on HbA1c and/or waist  
154 circumference. This initial protocol and the subsequent power calculations were, however, amended.

155 In the revised protocol, as reported here, the primary study outcome assessment is based on the overall effects  
156 in the total group, with the analyses by subgroup reported as supplementary information. This means that the  
157 main analyses will not be adjusted for multiple testing, which is in line with current recommendations(11).  
158 Additionally, the revised power calculations now include a variation inflation factor, also known as the design  
159 effect, to take the cluster randomisation into account. For the power calculations, we assumed an intraclass  
160 correlation coefficient (ICC) of 0.01. This was based on prior observations that intent-to-change behaviours  
161 related to diet and physical activity which are generally not very strongly clustered. The findings in previous  
162 work report that median ICCs in primary care lay around 0.01(12, 13). This may overestimate the impact, as  
163 inclusion of baseline co-variates, as planned in the current protocol, have been shown to reduce the design  
164 effect, e.g. to a median of 0.005 for ICCs in primary care(13, 14). Nevertheless, such a correction reduces the  
165 power of the study as compared to analyses that do not account for design effects.

166 With this new focus and design effect the power of the study can be calculated as follows. Assuming that event  
167 rates for T2D for usual care are 6.8% per year(15), the study has 81% power to identify at  $p < 0.05$  a reduction in  
168 T2D incidence of 35%(8), after a follow-up period of three years with an estimated drop-out rate of 10%. The  
169 study was, thus, sufficiently powered for the primary outcome. Since secondary outcomes are of continuous  
170 nature, it is expected that a statistically significant change can already be detected after one year of follow-up  
171 (*Table 1*).

172

173

174

175

176

177 **Table 1: Detectable difference in secondary study outcomes after one year of follow-up.**

Measure	Expected SD	Detectable difference		
		0% Dropout	10% Dropout	20% Dropout
Waist (cm)	11.5	1.23	1.28	1.34
Weight (kg)	7.5	0.80	0.84	0.88
Glucose (mmol/L)	0.6	0.06	0.07	0.07
HbA1c (%)	0.5	0.05	0.06	0.06
HOMA	3.0	0.32	0.33	0.35
Total cholesterol (mmol/L)	0.9	0.10	0.10	0.11
Triglycerides (mg/dL)	1.9	0.20	0.21	0.22
Blood pressure systolic (mmHg)	16	1.71	1.78	1.87
Blood pressure diastolic (mmHg)	8.6	0.92	0.96	1.00
Dietary intake (Kcal)	390	41.7	43.4	45.5

178 *Expected detectable difference for a range of secondary study outcomes after 1 year of follow-up, assuming i)*  
 179 *standard deviation (SD) of 10 cm with a two-sided 5% significance level and ii) ICC of 0.01. iii) a two sided p-*  
 180 *value of 0.05 iv) a power of 0.80.*

181

182 **Statistical analysis plan**

183 General principles

184 The analysis of the primary outcome will be performed after three years of follow-up. Secondary outcomes will  
 185 be evaluated both after one and three years of follow-up. Analyses will be performed by investigators of the  
 186 iHealth-T2D study group (MM for the 1-year analyses), who were blinded for the intervention, on a clean  
 187 anonymised data set (JCC and AK). The latest version of the R statistical software package will be used. Tests

188 will be two-sided and  $p$ -values  $<0.05$  will be considered statistically significant. We will not adjust for multiple  
189 testing as we pre-defined primary and secondary outcomes (11). Data will be reported in line with the  
190 Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement (16).

191 The analyses will be performed according to the intention-to-treat (ITT) principle with data from all participants  
192 enrolled in the study (17). Data of participants who attended at least one post-baseline assessment will be  
193 analysed according to their initially assigned study arm, regardless of their adherence. Participants who  
194 withdrew their consent will be excluded from the ITT analyses, the number of participants who withdrew  
195 consent and reasons for withdrawing consent will be reported. The patterns of missing data for primary and  
196 secondary outcomes and, if known, reasons for missingness, will be summarised for both treatment arms (18).  
197 The nature and pattern of missing data will be explored. If data missing at random is assumed, data will be  
198 imputed by multiple imputation methods, if data is not missing at random a 'best case/worst case' sensitivity  
199 analysis will be used (19). In case multiple imputation is used for one or more outcomes, variables selected as  
200 predictors for imputation contain known predictors of T2D. These include co-variables included in the main  
201 analysis model (sex, age) and the auxiliary variables country, setting, socio-economic status, pack-years of  
202 smoking, alcohol consumption, metabolic equivalents (METs) of physical activity, waist circumference and  
203 HbA1c. Missing values will be imputed separately by allocated randomisation group (20), and will comply with  
204 the multi-level character of the data.

205 All statistical analyses will be adjusted for confounders registered at baseline, namely age and sex.

#### 206 Baseline characteristics

207 Baseline characteristics of both study arms will be presented by sex and country and presented in a table. The  
208 baseline characteristics will not be tested for statistical differences between study arms (21). The baseline  
209 characteristics will be reported by arithmetic means and standard deviation (normally distributed numerical  
210 data), medians and interquartile ranges (non-normally distributed numerical data) or percentages and numbers  
211 (categorical data). Normality of data distributions will be inspected visually by plotting histograms and we will  
212 assess the deviation from normality by the Shapiro-Wilks test. In case of a  $p$ -value  $>0.05$  the data will be  
213 transformed for normality.

214 Descriptive characteristics to report at baseline include: age (years), setting (%), socio-economic status (%),  
215 smoking (pack-years), alcohol consumption (units/week), physical activity (MET/week), BMI ( $\text{kg}/\text{m}^2$ ), waist  
216 circumference (cm), HbA1c (%), and glucose (mmol/L). The descriptive characteristics will be reported by  
217 treatment arm. The population size and number of missing observations will also be reported.

#### 218 Analyses of primary outcome

219 Cumulative incidence of T2D will be summarized and compared between treatment arms using random effects  
220 logistic regression to estimate odds ratios (OR) and 95% CI. In addition we will evaluate intraclass correlation  
221 coefficients to assess cluster variance. The model will include the randomisation stratum site as a random  
222 effect and country as a fixed effect. The effectiveness of the lifestyle intervention will be reported by the  
223 screening numbers needed to identify one case of 'high risk' for developing diabetes and the number needed  
224 to treat or delay one case of T2D. The Wilson score method will be used to calculate CIs (22).

#### 225 Analyses of secondary outcomes

226 The secondary outcomes are of continuous nature and will be reported as mean and SD in each of the two  
227 treatment groups. The differences between the two treatment arms will be estimated with a multilevel linear  
228 mixed-effects regression model. The models will include the stratification variable site as a random effect and  
229 country as a fixed effect to adjust for potential cluster differences. The estimates will be presented with their  
230 associated 95% confidence intervals (CIs) and *p*-values for comparison between the treatment groups. In  
231 addition, adjustment for age and sex will be performed and the baseline values will be reported.

#### 232 Additional analyses

233 Treatment compliance will be reported for the intervention arm as an explanatory variable. It will be reported  
234 according to the number of times a participant turned up for the lifestyle modification (LSM) sessions. In  
235 addition, change in dietary intake will be reported. 24-h dietary recalls and food-frequency questionnaires were  
236 performed in the treatment arm only. Dietary variables will, therefore, be reported as change from baseline in  
237 the treatment arm.

238 Both absolute and relative risk reduction will be compared for subgroups of participants included in the study  
239 based upon a high risk for T2D according to waist circumference measurements and those included based upon

240 HbA1c levels. The interaction of treatment arm with sex, setting, socio-economic status, baseline waist  
241 circumference and HbA1c levels will be assessed. If there is an interaction, effect estimate and *p*-values will be  
242 presented by subgroups.

243 Sensitivity analyses will be performed to identify potentially extreme centres, because extreme deviation of  
244 one site from other sites may have a large impact on the overall results.

245 Since lifestyle interventions are generally considered to be safe, no (serious) adverse events are to be expected.  
246 In case of any adverse events these will be reported per incident with the number per group and a description  
247 of the event.

## 248 **Discussion**

249 The iHealth-T2D cluster RCT will provide evidence whether an intensive family-based lifestyle modification  
250 programme delivered by community health workers compared to usual care is effective to prevent T2D  
251 amongst South Asians at high risk for T2D based on central obesity or pre-diabetes, and living in India, Pakistan,  
252 Sri Lanka and the UK. Here we have provided details of the planned statistical analyses of the iHealth-T2D  
253 cluster RCT and pre-specified primary and secondary outcomes, both after one and three years of follow-up,  
254 together with planned analyses. Statistical decisions may influence final conclusions of the intervention's  
255 effectiveness. Reporting the SAP before commence of analyses increases transparency (9) and reduces the risk  
256 of bias by outcome reporting and data-driven analyses (23). This SAP contains details on all elements of the  
257 statistical analyses limiting the risk of bias, e.g. by reporting only outcomes for which a statically significant  
258 effect was identified (23).

259 Although statistical methods are chosen as objectively as possible, there is always unavoidable subjectivity  
260 involved. In addition, multiple perspectives may be relevant to each statistical discussion which may lead to  
261 different choices. In addition, chosen thresholds may be somewhat arbitrary. An example is the common use of  
262 *p*-values which is currently under debate (24). We will report *p*-values and label <0.05 as statistically significant,  
263 but will also consider effect sizes to help identify the effectiveness of the trial. Reporting a statistical analysis  
264 plan will help to counteract selection bias considering not reporting study results above the *p*-value threshold,  
265 since it promotes publication of non-significant findings (25). This will make the cumulative evidence of  
266 multiple individual studies more reliable.

267 The analyses will be based on ITT, which is currently considered as the golden standard for RCTs (17). In ITT  
268 based analyses subjects that did not comply with the assigned treatment of the study arm or dropped out of  
269 the study are still included in the analyses according to their assigned study arm. A drawback of this approach is  
270 that the effect size of the treatment will thus be underestimated, and results may be more susceptible to type  
271 II errors. In addition, interpretability might become difficult since dose-response is unclear. An advantage of the  
272 ITT is that participants that are less likely to comply with the intervention and are thus more likely to drop out  
273 are still included in the study results. The ITT approach will thus give study results that take likelihood of  
274 adopting the lifestyle intervention in the general population into account. Altogether, the analyses based on ITT  
275 will be conservative, but mostly unbiased since balance in participants generated by the random treatment  
276 allocation is maintained.

277 Multiple imputation will be used in case data missing at random can be assumed. However, none of the  
278 statistical techniques currently available can completely compensate for the lack of true data. In addition, the  
279 estimates of treatment effect only remain unbiased in case the analysis model is correctly specified (20). Bias is  
280 minimised if imputation is carried out separately by randomisation group. This approach may, however, be less  
281 conservative. Participants with missing data are more likely to be non-compliant with the lifestyle intervention,  
282 while imputed data may reflect those without missing data in the treatment arm. Other approaches to deal  
283 with missing data include last observation carried forward and complete-case analysis, but both are sensitive to  
284 generate biased estimates, and we therefore did not consider these approaches (26).

285 In conclusion, providing the details of the SAP for the iHealth-T2D trial will help to minimise bias in publication  
286 of our study outcomes. The selected statistical methods were based on current consensus on the most  
287 appropriate methods according to scientific literature, but are always under debate. Sensitivity analyses will,  
288 therefore, include conservative estimates of the effect of the iHealth-T2D trial. If the iHealth-T2D intervention  
289 is proven effective, this family-based lifestyle modification is designed in a way that it may be used in a wide-  
290 range of settings, including those with a low availability of resources, to prevent T2D among South Asians.

## 291 **Trial status**

292 Version: 1.0 Date: February 7, 2020

293 This document has been written based on information contained in the Clinical Study Protocol version 2, dated  
294 01/11/2016.

295 SAP revision history:

Protocol version	Updated SAP version	Section number changed	Description of and reason for change	Date changed
------------------	---------------------	------------------------	--------------------------------------	--------------

296

297 The first participant was enrolled at 15/06/2016 and the last participant at 05/03/2019. The last scheduled  
298 follow-up data is 05/03/2022.

299 **List of abbreviations**

300 CI – Confidence interval

301 CONSORT - Consolidated Standards of Reporting Trials

302 CRT – Controlled randomized trial

303 ICC – Intraclass Correlation Coefficient

304 ITT – Intention to treat

305 LSM – Lifestyle modification

306 MET - Metabolic equivalents

307 OR – Odds ratio

308 SAP – Statistical Analysis Plan

309 SD – Standard deviation

310 T2D – Type 2 diabetes

311 **Declarations**

312 *Ethics approval and consent to participate*

313 Ethical approval was obtained from the Institutional Review Board in each participating country and at each  
314 research location before the start of the study. Information sheets and consent forms were made available in  
315 the major South Asian languages. Multilingual translators were available as required. Each participant provided  
316 informed consent. People unwilling or unable to provide consent were excluded from the study.

317 *India*

- 318 • Max Healthcare Institutional Ethic Committee (ref: CT/MSSH/SKT-2/ENDO/IEC/14-40, date 22/04/16)
- 319 • Indian Council for Medical Research (ICMR, ref: 55/7/Indo-Foreign-Diab/2014-NCD-II, date 08/02/2016)

320

321 *Pakistan*

- 322 • Punjab Institute of Cardiology Ethical Committee (ref: rtpgme-research-047, date 09/04/16)
- 323 • Services Institute of Medical Sciences Institutional Review Board (ref: IRB/2016/222/SIMS, date 12/03/16)

324

325 *Sri Lanka*

- 326 • University of Colombo Ethics Review Committee (ref: EC-16-063, date 23/05/16)
- 327 • University of Kelaniya Ethics Review Committee (ref: P/62/05/2016, date 11/05/16)

328

329 *UK*

- 330 • West Midlands - Solihull Research Ethics Committee (ref: 16/WM/0171, date 14/04/2016)

331

332 *Consent for publication*

333 Not applicable, no datasets are included in this SAP.

334 *Availability of data and materials*

335 Data will be available to others on completion of the research, by application to the Steering Committee.

336 *Competing interests*

337 The authors have no competing interests to declare.

338 *Funding*

339 The iHealth-T2D trial was funded by the European Commission (Grant award 643774, January 2015 to  
340 December 2019).

341 *Authors' contributions*

342 MM drafted and edited the manuscript. SP and IGMV reviewed and edited the manuscript. GSF, HMG, MRJ,  
343 RPRE, SA, SJ, AK, PK, KIK, JSK, RW, and JCC designed the iHealth-T2D trial. All authors reviewed the manuscript.  
344 All authors read and approved the final manuscript.

345 *Acknowledgements*

346 We are most grateful to the participants of the iHealth-T2D study, and all the staff members who have taken  
347 part in gathering the data of this study.

348

349

350

351

352

353

354

355

356

357

358

## 359 References

- 360 1. Balakumar P, Maung-U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and  
361 diabetes mellitus. *Pharmacological Research*. 2016;113:600-9.
- 362 2. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control  
363 and vascular outcomes in patients with type 2 diabetes. *The New England journal of medicine*.  
364 2008;358(24):2560-72.
- 365 3. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities  
366 and differences with white Caucasian and other populations. *Annals of the New York Academy of Sciences*.  
367 2013;1281:51-63.
- 368 4. Meeks KA, Freitas-Da-Silva D, Adeyemo A, Beune EJ, Modesti PA, Stronks K, et al. Disparities in type 2  
369 diabetes prevalence among ethnic minority groups resident in Europe: a systematic review and meta-analysis.  
370 *Internal and emergency medicine*. 2016;11(3):327-40.
- 371 5. Ramachandran A, Snehalatha C, Samith Shetty A, Nanditha A. Primary prevention of Type 2 diabetes in  
372 South Asians--challenges and the way forward. *Diabetic medicine : a journal of the British Diabetic Association*.  
373 2013;30(1):26-34.
- 374 6. Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes  
375 Prevention Study (DPS). *Diabetes Care*. 2003;26(12):3230.
- 376 7. Diabetes Prevention Program Research G. The Diabetes Prevention Program (DPP): description of  
377 lifestyle intervention. *Diabetes care*. 2002;25(12):2165-71.
- 378 8. Jenum AK, Brekke I, Mdala I, Muilwijk M, Ramachandran A, Kjollesdal M, et al. Effects of dietary and  
379 physical activity interventions on the risk of type 2 diabetes in South Asians: meta-analysis of individual  
380 participant data from randomised controlled trials. *Diabetologia*. 2019;62(8):1337-48.
- 381 9. Gamble C, Krishan A, Stocken D, Lewis S, Juszcak E, Doré C, et al. Guidelines for the Content of  
382 Statistical Analysis Plans in Clinical Trials. *JAMA*. 2017;318(23):2337-43.
- 383 10. Kumar R, Nandhini LP, Kamalanathan S, Sahoo J, Vivekanadan M. Evidence for current diagnostic  
384 criteria of diabetes mellitus. *World J Diabetes*. 2016;7(17):396-405.
- 385 11. Feise RJ. Do multiple outcome measures require p-value adjustment? *BMC Med Res Methodol*.  
386 2002;2:8-.
- 387 12. Thompson DM, Fernald DH, Mold JW. Intraclass correlation coefficients typical of cluster-randomized  
388 studies: estimates from the Robert Wood Johnson Prescription for Health projects. *Annals of family medicine*.  
389 2012;10(3):235-40.
- 390 13. Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-cluster  
391 correlation from primary care research to inform study design and analysis. *Journal of clinical epidemiology*.  
392 2004;57(8):785-94.
- 393 14. Wright N, Ivers N, Eldridge S, Taljaard M, Bremner S. A review of the use of covariates in cluster  
394 randomized trials uncovers marked discrepancies between guidance and practice. *Journal of clinical*  
395 *epidemiology*. 2015;68(6):603-9.
- 396 15. Chambers JC, Loh M, Lehne B, Drong A, Kriebel J, Motta V, et al. Epigenome-wide association of DNA  
397 methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a  
398 nested case-control study. *Lancet Diabetes Endocrinol*. 2015;3(7):526-34.
- 399 16. CONSORT. <http://www.consort-statement.org/consort-20102010>.
- 400 17. Gupta SK. Intention-to-treat concept: A review. *Perspect Clin Res*. 2011;2(3):109-12.
- 401 18. García-Laencina PJ, Sancho-Gómez J-L, Figueiras-Vidal AR. Pattern classification with missing data: a  
402 review. *Neural Computing and Applications*. 2010;19(2):263-82.
- 403 19. Dziura JD, Post LA, Zhao Q, Fu Z, Peduzzi P. Strategies for dealing with missing data in clinical trials:  
404 from design to analysis. *Yale J Biol Med*. 2013;86(3):343-58.
- 405 20. Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ. Should multiple imputation be the method of choice  
406 for handling missing data in randomized trials? *Stat Methods Med Res*. 2018;27(9):2610-26.
- 407 21. de Boer MR, Waterlander WE, Kuijper LDJ, Steenhuis IHM, Twisk JWR. Testing for baseline differences  
408 in randomized controlled trials: an unhealthy research behavior that is hard to eradicate. *Int J Behav Nutr Phys*  
409 *Act*. 2015;12:4-.
- 410 22. Bender R. Calculating Confidence Intervals for the Number Needed to Treat. *Controlled Clinical Trials*.  
411 2001;22(2):102-10.
- 412 23. Finfer S, Bellomo R. Why publish statistical analysis plans? *Critical care and resuscitation : journal of*  
413 *the Australasian Academy of Critical Care Medicine*. 2009;11(1):5-6.

- 414 24. Amrhein V, Korner-Nievergelt F, Roth T. The earth is flat ( $p > 0.05$ ): significance thresholds and the  
415 crisis of unreplicable research. *PeerJ*. 2017;5:e3544.
- 416 25. Perneger TV, Combesure C. The distribution of P-values in medical research articles suggested  
417 selective reporting associated with statistical significance. *Journal of clinical epidemiology*. 2017;87:70-7.
- 418 26. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat  
419 analysis. *Clin Trials*. 2012;9(4):396-407.

420

421 Figure 1: Study Flow

All rights reserved. No reuse allowed without permission.

